Attentrol
Attentrol contains Atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of norepinephrine, a natural chemical in the brain, which helps to increase attention span, concentration, and reduce impulsivity and hyperactivity in individuals with ADHD.
Dosage by Body Weight
Dosage is highly individualized and determined based on patient weight and clinical response. For children and adolescents weighing up to 70 kg, dosing is initiated at approximately 0.5 mg/kg/day and titrated after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg/day. For patients weighing over 70 kg, the starting dose is 40 mg/day, increased to a target of 80 mg/day after 3 days.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and efficacy have not been established in patients in this weight range or in children under 6 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Safety and efficacy have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not routine
- Frequency
- Use only if specifically prescribed by a specialist
- Tracking Notes
- Atomoxetine is generally not approved for pediatric patients under 6 years of age.
- Body Weight
- 11-15 kg
- Dose
- Starting: 5 mg to 7.5 mg daily; Target: 13 mg to 18 mg daily
- Frequency
- Once daily in the morning, or divided equally twice daily
- Tracking Notes
- Calculated based on 0.5 mg/kg/day (start) to 1.2 mg/kg/day (target). Use with extreme caution under strict pediatric monitoring.
- Body Weight
- 16-20 kg
- Dose
- Starting: 10 mg daily; Target: 20 mg to 24 mg daily
- Frequency
- Once daily in the morning, or divided equally into morning and late afternoon
- Tracking Notes
- Calculated based on 0.5 mg/kg/day (start) to 1.2 mg/kg/day (target). Dose can be adjusted depending on clinical response and tolerability.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Do not use | Safety and efficacy have not been established in patients in this weight range or in children under 6 years of age. |
| 5-7 kg | Not recommended | Do not use | Safety and efficacy have not been established. |
| 8-10 kg | Not routine | Use only if specifically prescribed by a specialist | Atomoxetine is generally not approved for pediatric patients under 6 years of age. |
| 11-15 kg | Starting: 5 mg to 7.5 mg daily; Target: 13 mg to 18 mg daily | Once daily in the morning, or divided equally twice daily | Calculated based on 0.5 mg/kg/day (start) to 1.2 mg/kg/day (target). Use with extreme caution under strict pediatric monitoring. |
| 16-20 kg | Starting: 10 mg daily; Target: 20 mg to 24 mg daily | Once daily in the morning, or divided equally into morning and late afternoon | Calculated based on 0.5 mg/kg/day (start) to 1.2 mg/kg/day (target). Dose can be adjusted depending on clinical response and tolerability. |
Formulation
Purpose
Used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older, adolescents, and adults.
Generic Name
AtomoxetineScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.